Search

Your search keyword '"Dusi, Daniele"' showing total 3 results
Start Over Author "Dusi, Daniele" Search Limiters Full Text
3 results on '"Dusi, Daniele"'

1. Mental Health Consequences of the COVID-19 Pandemic Long-Term Exposure in Italian Dermatologists

Author

Ciuluvica, Cristina, primary, Gualdi, Giulio, additional, Dal Canton, Marco, additional, Fantini, Fabrizio, additional, Paradisi, Andrea, additional, Sbano, Paolo, additional, Simonacci, Marco, additional, Dusi, Daniele, additional, Vezzoni, Gian Marco, additional, D’Acunto, Carmine, additional, Lombardo, Maurizio, additional, Zanchi, Malvina, additional, Alfredo, Zucchi, additional, Eisendle, Klaus, additional, Prignano, Francesca, additional, and Amerio, Paolo, additional

Published
2021
Full Text
View/download PDF

2. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study

Author

A, Costanzo, L, Bianchi, M L, Flori, G, Malara, L, Stingeni, M, Bartezaghi, L, Carraro, G, Castellino, Bottoni, Ugo, Brazzelli, Valeria, Burlando, Martina, Cantoresi, Franca, Capo, Alessandra, Cattaneo, Angelo, Cusano, Francesco, Dapavo, Paolo, Del Giglio, Micol, Di Lernia, Vito, Di Nuzzo, Sergio, Dusi, Daniele, Concetta Fargnoli, Maria, Franchi, Chiara, Galluzzo, Marco, Ghilardi, Alberto, Hansel, Katharina, Loconsole, Francesco, Lora, Viviana, Malagoli, Piergiorgio, Mastrandrea, Valentina, Raffaele Mercuri, Santo, Letizia Musumeci, Maria, Naldi, Luigi, Narcisi, Alessandra, Offidani, Annamaria, Pagnanelli, Gianluca, Papini, Manuela, Patrizi, Annalisa, Pau, Monica, Pellacani, Giovanni, Peris, Ketty, Persechino, Severino, Piaserico, Stefano, Pietroleonardo, Lucia, Prignano, Francesca, Reseghetti, Alberto, Romanelli, Marco, Russo, Filomena, Sirna, Riccardo, Skroza, Nevena, Stinco, Giuseppe, Trevisini, Sara, Zane, Cristina, Zichichi, Leonardo, Zini, Antonio, Megna, Matteo, Ketty Peris (ORCID:0000-0002-5237-0463), A, Costanzo, L, Bianchi, M L, Flori, G, Malara, L, Stingeni, M, Bartezaghi, L, Carraro, G, Castellino, Bottoni, Ugo, Brazzelli, Valeria, Burlando, Martina, Cantoresi, Franca, Capo, Alessandra, Cattaneo, Angelo, Cusano, Francesco, Dapavo, Paolo, Del Giglio, Micol, Di Lernia, Vito, Di Nuzzo, Sergio, Dusi, Daniele, Concetta Fargnoli, Maria, Franchi, Chiara, Galluzzo, Marco, Ghilardi, Alberto, Hansel, Katharina, Loconsole, Francesco, Lora, Viviana, Malagoli, Piergiorgio, Mastrandrea, Valentina, Raffaele Mercuri, Santo, Letizia Musumeci, Maria, Naldi, Luigi, Narcisi, Alessandra, Offidani, Annamaria, Pagnanelli, Gianluca, Papini, Manuela, Patrizi, Annalisa, Pau, Monica, Pellacani, Giovanni, Peris, Ketty, Persechino, Severino, Piaserico, Stefano, Pietroleonardo, Lucia, Prignano, Francesca, Reseghetti, Alberto, Romanelli, Marco, Russo, Filomena, Sirna, Riccardo, Skroza, Nevena, Stinco, Giuseppe, Trevisini, Sara, Zane, Cristina, Zichichi, Leonardo, Zini, Antonio, Megna, Matteo, and Ketty Peris (ORCID:0000-0002-5237-0463)

Published
2018

3. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. SUPREME study

Author

Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., Bottoni, U, Brazzelli, V, Burlando, M, Cantoresi, F, Capo, A, Cattaneo, A, Cusano, F, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, Dusi, D, Fargnoli, Mc, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Mastrandrea, V, Megna, M, Mercuri, Sr, Letizia Musumeci, M, Naldi, L, Narcisi, A, Offidani, A, Pagnanelli, G, Papini, M, Patrizi, A, Pau, M, Pellacani, G, Peris, K, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Romanelli, M, Russo, F, Sirna, R, Skroza, N, Stinco, G, Trevisini, S, Zane, C, Zichichi, L, Zini, A., Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., Persechino, Severino, Pau, Monica, Cusano, Francesco, Russo, Filomena, Stinco, Giuseppe, Ghilardi, Alberto, Del Giglio, Micol, De Luca, Giuseppe, Brazzelli, Valeria, Fargnoli, Maria Concetta, Capo, Alessandra, Mastrandrea, Valentina, Piaserico, Stefano, Franchi, Chiara, Zane, Cristina, Cattaneo, Angelo, Galluzzo, Marco, La Selva, Roberta, Di Nuzzo, Sergio, Megna, Matteo, Pellacani, Giovanni, Peris, Ketty, Patrizi, Annalisa, Trevisini, Sara, Pagnanelli, Gianluca, Skroza, Nevena, Malagoli, Piergiorgio, Resghetti, Alberto, Burlando, Martina, Loconsole, Francesco, Offidani, Anna Maria, Albertini, Giuseppe, Mercuri, Santo Raffaele, Bottoni, Ugo, Dusi, Daniele, Zini, Antonio, Pietroleonardo, Lucia, Cantoresi, Franca, Sirna, Riccardo, Lora, Viviana, Hansel, Katharina, Prignano, Francesca, and Natalini, Ylenia

Subjects
Adult, Male, medicine.medical_specialty, Psoriasis, secukinumab, Genotyping Techniques, Dermatology, HLA-C Antigens, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Antibodies, 030207 dermatology & venereal diseases, 03 medical and health sciences, Antibodies, Monoclonal, Biomarkers, Female, Genetic Predisposition to Disease, Humans, Interleukin-17, Italy, Middle Aged, Prospective Studies, Psoriasis, Treatment Outcome, 0302 clinical medicine, Internal medicine, Severity of illness, Monoclonal, medicine, Clinical endpoint, Adverse effect, Prospective cohort study, Humanized, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, medicine.disease, Confidence interval, 030220 oncology & carcinogenesis, Secukinumab, Interleukin 17, business
Abstract

Background Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers. Objectives To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis. Methods SUPREME was a 24-week, phase IIIb study with an extension period up to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90 response rate after 16 weeks. Results In total, 434 patients were recruited: 185 (42·6%) were Cw6-POS and 246 (56·7%) were Cw6-NEG (three not assessed). Mean ± SD age was 45·2 ± 13·2 years (Cw6-POS 42·7 ± 13·1; Cw6-NEG 47·2 ± 12·9). The baseline PASI score was comparable between the cohorts [Cw6-POS 20·7 ± 8·99; Cw6-NEG 21·5 ± 9·99 (P = 0·777)]. At week 16, PASI 90 was achieved in 80·4% of Cw6-POS and 79·7% of Cw6-NEG patients (difference 0·76; 95% confidence interval -7·04 to 8·23). No differences in absolute PASI at week 16 (Cw6-POS 1·36 ± 3·58; Cw6-NEG 1·18 ± 2·29) were observed. The overall safety profile of secukinumab was consistent with that previously reported. No statistically significant difference was detected in the rate of treatment-emergent adverse events [Cw6-POS 42·7%; Cw6-NEG 49·6% (P = 0·295)]. A high PASI 90 response was achieved with secukinumab with a fast reduction in absolute PASI. Conclusions Determination of HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of HLA-Cw6 status.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results